Stock listing

Lang & Schwarz:A2QJRW BioInvent International AB Aktie

German listing (Lang & Schwarz) of BioInvent International AB · home listing Stockholm:BINV

Follow BioInvent International AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:BINV

4.30 SEK -1.13 (-20.8%)

Close on Nov 2, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:BINV

Past year -87.3% · daily closes, Nov 3, 2025 – Nov 2, 2026, adjusted for splits
Day range
4.10 – 5.10 SEKNov 2, 2026
Volume
2.56M sharesNov 2, 2026
Market cap
283.0M SEKAt the close on Nov 2, 2026 · price × 65.80M shares outstanding
52-week range
4.10 – 34.85 SEKLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
Traded on an average day
2.86M SEKMedian day 72,711 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
BioInvent International AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:BINV · Home4.30 SEK-1.13 (-20.8%)2,560,5035.105.104.105.43Close on Nov 2, 2026
Frankfurt:BIX0€1.798 EUR+0.024 (+1.4%)—€1.798€1.798€1.798€1.774Close on Oct 27, 2026

Daily closes

Last 3 months, Aug 3, 2026 – Nov 2, 2026 · OMXSTO:BINV · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
4.30-1.13-20.8%5.105.104.102,560,503
5.43-0.28-4.9%5.856.195.241,513,922
5.71-14.99-72.4%11.5011.505.366,109,655
20.70-0.10-0.5%20.7021.9020.45151,421
20.80+0.30+1.5%20.6521.3020.2098,643
20.50+0.25+1.2%20.5021.1518.40279,537
20.25-0.25-1.2%20.6021.4020.2573,550
20.500.000.0%21.2021.2020.5071,982
20.50-1.05-4.9%22.2522.2520.30178,086
21.55-0.05-0.2%21.6021.9020.9564,014
21.60-1.80-7.7%23.4023.5521.30138,007
23.40-0.10-0.4%23.5523.8523.3070,486
23.50+0.35+1.5%23.3024.0022.90127,653
23.150.000.0%23.2523.4523.1529,387
23.15+0.05+0.2%23.0523.7023.0550,021
23.10-0.10-0.4%23.2023.5523.0071,460
23.20+0.15+0.7%23.0523.6023.0057,746
23.05-0.20-0.9%23.1523.7523.0072,271
23.25+0.20+0.9%22.8023.3522.8072,062
23.05+0.15+0.7%22.9523.2022.8036,537
22.900.000.0%22.8523.2522.8545,087
22.90+0.40+1.8%22.5523.1522.4558,310
22.50-0.45-2.0%22.9522.9522.5097,493
22.95+0.45+2.0%22.4523.1022.4539,511
22.50-0.20-0.9%22.8522.9522.4043,713
22.70+0.45+2.0%22.2523.1522.2573,308
22.25+1.45+7.0%21.1522.2521.05132,635
20.80-1.40-6.3%22.0022.0020.80140,629
22.200.000.0%22.1522.8521.8079,580
22.20+0.30+1.4%22.1522.4522.0030,610
21.90-0.45-2.0%22.2022.4521.9051,766
22.35-0.05-0.2%22.4022.9522.0058,186
22.40-0.15-0.7%22.4522.7021.70114,060
22.55-0.05-0.2%22.7522.8522.4041,215
22.60+0.25+1.1%22.5522.7022.1064,422
22.35-0.35-1.5%22.7522.7522.2557,054
22.70-0.20-0.9%22.7523.0022.4579,179
22.90-0.05-0.2%23.0023.4522.7065,502
22.95-0.75-3.2%23.8524.0022.70141,751
23.70-0.05-0.2%23.6023.9523.3084,982
23.75-0.55-2.3%24.2024.2523.4063,851
24.30+0.65+2.7%23.9024.3023.55120,228
23.65-0.85-3.5%24.3524.6523.50110,119
24.50+1.45+6.3%23.2024.6523.00100,639
23.05+0.30+1.3%23.0523.3522.6570,473
22.75-0.75-3.2%23.5023.6522.3089,351
23.50+0.90+4.0%22.3024.0022.30145,615
22.60-0.90-3.8%22.0523.6521.00336,958
23.50-0.80-3.3%24.3524.3523.3596,708
24.300.000.0%24.5024.6024.0573,151
24.30+0.10+0.4%24.2525.0023.8562,054
24.20+1.20+5.2%23.1024.2022.55127,872
23.00-0.95-4.0%24.0524.5522.80127,350
23.95+0.50+2.1%23.6024.1022.9567,338
23.45-1.10-4.5%25.2025.2023.4553,959
24.55-0.35-1.4%25.1025.2024.4056,443
24.90-0.20-0.8%25.1025.2524.4563,263
25.10+1.30+5.5%23.7525.1023.7590,302
23.80+0.85+3.7%23.1023.8522.7064,074
22.95-0.20-0.9%23.1523.3522.8554,337
23.15+0.15+0.7%23.0023.5522.80125,026
23.00+1.40+6.5%21.7024.6521.65366,972
21.60-1.15-5.1%22.8523.1521.15206,384
22.75-0.30-1.3%23.0523.3022.5569,450
23.05+0.30+1.3%22.7523.4522.6536,641
22.75-0.20-0.9%22.9523.0522.4527,375
Ticker
Lang & Schwarz:A2QJRW
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • Bioinvent International (Stockholm:BINV) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:00 AM ET

    Watch Transcript

  • Bioinvent International (Stockholm:BINV) Q3 2025 Earnings Call

    Wed, Oct 29, 2025 · 9:00 AM ET

    Watch Transcript

Latest news

BioInvent International resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026

Oct 28, 2026

Closed 5.71 (-72.4%) on Oct 29, 2026

BioInvent International to present BI-1808 data in platinum-resistant recurrent ovarian cancer at ESMO 2026

Oct 18, 2026

Closed 21.60 (-7.7%) on Oct 19, 2026

BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology

Jun 1, 2026

Closed 31.10 (-6.0%) on Jun 1, 2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

May 12, 2026

Closed 21.25 (-11.1%) on May 12, 2026

BioInvent International AB: Interim Report January - March 2026

Apr 29, 2026

Closed 22.40 (+3.9%) on Apr 29, 2026

BioInvent International AB Publishes Annual Report 2025

Mar 31, 2026

Closed 22.25 (+2.3%) on Mar 31, 2026

BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis

Mar 26, 2026

Closed 22.60 (-3.8%) on Mar 26, 2026

Notice to Annual General Meeting in BioInvent International AB

Mar 24, 2026

Closed 22.15 (-0.4%) on Mar 24, 2026

BioInvent International AB: Year-End Report January 1 - December 31, 2025

Feb 26, 2026

Closed 23.30 (-11.4%) on Feb 26, 2026

Invitation to Presentation of BioInvent's Year-End Report 2025

Feb 26, 2026

Closed 23.30 (-11.4%) on Feb 26, 2026

All BioInvent International AB news

Financings

  • Rights offering of new shares with preferential rights

    Oct 28, 2026 · US$43.28M

    Announced: about SEK 430M · DNB Carnegie Investment Bank AB (publ)

    Dealers: DNB Carnegie Investment Bank AB (publ) (lead)

    Buyers: Redmile (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Van Herk (Subscription commitment; together with other existing shareholders approximately SEK 80 million); Forbion (Subscription commitment; together with other existing shareholders approximately SEK 80 million); HealthInvest (Subscription commitment; together with other existing shareholders approximately SEK 80 million); DNB Bank ASA (Guarantee undertakings, with others, up to approximately SEK 270 million); Schonfeld Global Master Fund L.P. (Guarantee undertakings, with others, up to approximately SEK 270 million); Anavio Capital Partners LLP (Guarantee undertakings, with others, up to approximately SEK 270 million)

    Insiders: Shareholding board members and management intend to subscribe approximately SEK 0.6 million in total, including pro rata from CEO Martin Welschof and Chairman Leonard Kruimer

    Use of proceeds: Strengthen financial position and fund clinical development of priority programs, principally BI-1808 and BI-1206 in solid tumors

    Announced Oct 28, 2026

Read by 6ix AI from the company's releases

Decks

BioInvent International AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 30 in all · newest Oct 28, 2026 · oldest 2025
Calls
2 calls with a replay · 2 with a transcript · latest Feb 26, 2026
Decks
15 decks · latest October 2026

Where BioInvent International AB is listed

ListingExchangeCountryCurrency
Stockholm:BINV · Home listingStockholmSwedenSEK
Aquis:BINVSAquisUnited KingdomSEK
Stuttgart:BIX0StuttgartGermanyEUR
LS Exchange:A2QJRWLS ExchangeGermanyEUR
Lang & Schwarz:A2QJRW · This pageLang & SchwarzGermanyEUR
gettex:BIX0gettexGermanyEUR
Frankfurt:BIX0FrankfurtGermanyEUR
Dusseldorf:BIX0DusseldorfGermanyEUR
LSIN:0H22LSINUnited KingdomSEK
Munich:BIX0MunichGermanyEUR
OTC:BOVNFOTCUnited StatesUSD
Aquis:BINVSAquisUnited KingdomSEK
Turquoise:BINVSTurquoiseUnited KingdomSEK

Log in to ask 6ix AI your own questions about BioInvent International AB.